Results 111 to 120 of about 1,690 (152)

Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study.

The Lancet Diabetes and Endocrinology
BACKGROUND Homozygous familial hypercholesterolaemia (HoFH) is a rare inherited disorder characterised by extremely high concentrations of LDL cholesterol, leading to early-onset atherosclerosis.
Luis Masana, Alberto Zambon, C. Schmitt, Christina Taylan, J. Driemeyer, Hofit Cohen, P. Buonuomo, A. Alashwal, M. Al-Dubayee, Naji Kholaif, J. Díaz-Díaz, Faouzi Maatouk, Sergio Martínez-Hervás, Brian Mangal, Sandra Löwe, T. Cunningham   +15 more
semanticscholar   +1 more source

Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients with Homozygous Familial Hypercholesterolemia: Study Protocol of the LILITH Study

European Atherosclerosis Journal
Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic disorder characterized by markedly elevated low-density lipoprotein cholesterol (LDL-C) levels from birth, leading to premature and severe cardiovascular disease.
A. Catapano, Marcello Arca, L. D’Erasmo   +2 more
semanticscholar   +1 more source

Metal complex lipid-based nanoparticles deliver metabolism-regulating lomitapide to overcome CTC immune evasion via activating STING pathway.

European journal of pharmaceutics and biopharmaceutics
Activating the cGAS-STING pathway of circulating tumor cell clusters (CTC clusters) represents a promising strategy to mitigate metastases. To fully exploit the potential of cholesterol-regulating agents in activating CTCs' STING levels, we developed a ...
Ni Fan, Feng Zhao, Yuanyuan Meng, Liqing Chen, Lin Miao, Ping Wang, Manqing Tang, Xuanjun Wu, Yingpeng Li, Yunfei Li, Zhonggao Gao   +10 more
semanticscholar   +1 more source

Abstract A038: Lomitapide enhances cytotoxic effects of temozolomide in chemo-resistant glioblastoma

Molecular Cancer Therapeutics
Glioblastoma is the most prevalent and aggressive malignant primary brain tumour in adults, with a median survival following multi-modality therapy of 14.6 months.
Alyona Ivanova, Taylor M Wilson, K. Ghannad-Zadeh, E. Tse, Robert Flick, M. Wu, Sunit Das   +6 more
semanticscholar   +1 more source

Sex-related differences in response to lomitapide in HoFH: A subanalysis of the Pan-European Lomitapide retrospective observational study.

Atherosclerosis
BACKGROUND AND AIMS Homozygous familial hypercholesterolemia (HoFH) is a hereditary lipid metabolism disorder characterized by severe elevation of low-density lipoprotein cholesterol (LDL-C) and heightened risk of premature atherosclerotic cardiovascular
C. Pavanello, P. Suppressa, S. Castiglione, A. Di Costanzo, D. Tramontano, L. Rizzi, K. Steward, Laura Calabresi, Marcello Arca, J. Roeters van Lennep, L. D’Erasmo, A. Cefalù, Antonella Giammanco, Maurizio Averna, G. Iannuzzo, I. Calcaterra, Matteo Nicola Dario Di Minno, Martina Ferrandino, Giuliana Fortunato, A. Pujia, T. Montalcini, Giovanni Battista Vigna, M. Bucci, K. Bonomo, B. Pino, Francesco Sbrana, A. Cesaro, Paolo Calabrò, S. D’Addato, E. Formisano, Livia Pisciotta, V. Kolovou, G. Kolovou, G. Anastasiou, E. Liberopoulos, Eugene Daphnis, J. Rutten, A. Vogt, J. Cegla, S. Walji, M. Kayikcioglu, José T Real, S. Martínez-Hervás, Avishay Elis, K. Littmann   +44 more
semanticscholar   +1 more source

Lomitapide reduces viability and clonogenicity in hepatocellular carcinoma cells but enhances xenograft growth: The importance of the tumor microenvironment.

Journal of Pharmacology and Experimental Therapeutics
Lomitapide, a microsomal triglyceride transfer protein inhibitor approved for the treatment of homozygous familial hypercholesterolemia, has recently attracted interest as a potential anticancer agent because of its effects on lipid metabolism. Given the
Carla G. Comanzo, Florencia Buatti Fagalde, M. C. Vera, L. Bustos, Nicolás F. Palma, Alejo M. Capiglioni, L. Hesse, G. Pisani, Anabela Ferretti, M. P. Ceballos, María de L. Alvarez, Ariel D. Quiroga   +11 more
semanticscholar   +1 more source

Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia

Liver International, 2023
Tiziana Montalcini, Tiziana Sampietro, Carlo Sabba   +2 more
exaly  

Targeting PP2A with lomitapide suppresses colorectal tumorigenesis through the activation of AMPK/Beclin1-mediated autophagy

Cancer Letters, 2021
Qian Zuo, Long Liao, Ya-Ping Liu
exaly  

Lomitapide for the treatment of pediatric homozygous familial hypercholesterolemia

Expert Opinion on Pharmacotherapy
A. Hooper, Damon A. Bell, John R. Burnett   +2 more
semanticscholar   +1 more source

Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)

Journal of Clinical Lipidology, 2020
Christopher P Cannon, Lukas Makris, Dirk J Blom   +2 more
exaly